These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 28507117)

  • 1. Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients.
    Van't Boveneind-Vrubleuskaya N; Seuruk T; van Hateren K; van der Laan T; Kosterink JGW; van der Werf TS; van Soolingen D; van den Hof S; Skrahina A; Alffenaar JC
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis.
    Ghimire S; Maharjan B; Jongedijk EM; Kosterink JGW; Ghimire GR; Touw DJ; van der Werf TS; Shrestha B; Alffenaar JC
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.
    Ghimire S; Van't Boveneind-Vrubleuskaya N; Akkerman OW; de Lange WC; van Soolingen D; Kosterink JG; van der Werf TS; Wilffert B; Touw DJ; Alffenaar JW
    J Antimicrob Chemother; 2016 Oct; 71(10):2691-703. PubMed ID: 27231277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study on the resistance of rifampicin-resistant Mycobacterium tuberculosis to anti-tuberculosis drugs in group A].
    Dai XW; Li CY; Wang NH; Chen SS; Tian LL; Zhao YF; Tao LY; Yang XY; Ding BC; He XX
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1110-1117. PubMed ID: 37914422
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis.
    Alsaad N; Dijkstra JA; Akkerman OW; de Lange WC; van Soolingen D; Kosterink JG; van der Werf TS; Alffenaar JW
    Antimicrob Agents Chemother; 2016 Jul; 60(7):3942-7. PubMed ID: 27067336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients.
    Alffenaar JW; van Altena R; Harmelink IM; Filguera P; Molenaar E; Wessels AM; van Soolingen D; Kosterink JG; Uges DR; van der Werf TS
    Clin Pharmacokinet; 2010 Aug; 49(8):559-65. PubMed ID: 20608757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.
    Bouton TC; Phillips PPJ; Mitnick CD; Peloquin CA; Eisenach K; Patientia RF; Lecca L; Gotuzzo E; Gandhi NR; Butler D; Diacon AH; Martel B; Santillan J; Hunt KR; Vargas D; von Groote-Bidlingmaier F; Seas C; Dianis N; Moreno-Martinez A; Horsburgh CR
    Trials; 2017 Nov; 18(1):563. PubMed ID: 29178937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis.
    Alsaad N; van Altena R; Pranger AD; van Soolingen D; de Lange WC; van der Werf TS; Kosterink JG; Alffenaar JW
    Eur Respir J; 2013 Aug; 42(2):504-12. PubMed ID: 23100498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate.
    Ahmed I; Jabeen K; Inayat R; Hasan R
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2522-5. PubMed ID: 23507286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis.
    Alsultan A; An G; Peloquin CA
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3800-7. PubMed ID: 25870068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis.
    Koh WJ; Lee SH; Kang YA; Lee CH; Choi JC; Lee JH; Jang SH; Yoo KH; Jung KH; Kim KU; Choi SB; Ryu YJ; Chan Kim K; Um S; Kwon YS; Kim YH; Choi WI; Jeon K; Hwang YI; Kim SJ; Lee YS; Heo EY; Lee J; Ki YW; Shim TS; Yim JJ
    Am J Respir Crit Care Med; 2013 Oct; 188(7):858-64. PubMed ID: 23927582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extensively and pre-extensively drug resistant tuberculosis in clinical isolates of multi-drug resistant tuberculosis using classical second line drugs (levofloxacin and amikacin).
    Mirza IA; Khan FA; Khan KA; Satti L; Ghafoor T; Fayyaz M
    J Coll Physicians Surg Pak; 2015 May; 25(5):337-41. PubMed ID: 26008658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.
    Deshpande D; Pasipanodya JG; Mpagama SG; Srivastava S; Bendet P; Koeuth T; Lee PS; Heysell SK; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S317-S326. PubMed ID: 30496457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study.
    Heysell SK; Mpagama SG; Ogarkov OB; Conaway M; Ahmed S; Zhdanova S; Pholwat S; Alshaer MH; Chongolo AM; Mujaga B; Sariko M; Saba S; Rahman SMM; Uddin MKM; Suzdalnitsky A; Moiseeva E; Zorkaltseva E; Koshcheyev M; Vitko S; Mmbaga BT; Kibiki GS; Pasipanodya JG; Peloquin CA; Banu S; Houpt ER
    Clin Infect Dis; 2023 Feb; 76(3):497-505. PubMed ID: 35731948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.
    Deshpande D; Pasipanodya JG; Mpagama SG; Bendet P; Srivastava S; Koeuth T; Lee PS; Bhavnani SM; Ambrose PG; Thwaites G; Heysell SK; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S293-S302. PubMed ID: 30496461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
    Mpagama SG; Ndusilo N; Stroup S; Kumburu H; Peloquin CA; Gratz J; Houpt ER; Kibiki GS; Heysell SK
    Antimicrob Agents Chemother; 2014; 58(2):782-8. PubMed ID: 24247125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis.
    van Rijn SP; van Altena R; Akkerman OW; van Soolingen D; van der Laan T; de Lange WC; Kosterink JG; van der Werf TS; Alffenaar JW
    Eur Respir J; 2016 Apr; 47(4):1229-34. PubMed ID: 26743484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis.
    van Altena R; Dijkstra JA; van der Meer ME; Borjas Howard JF; Kosterink JG; van Soolingen D; van der Werf TS; Alffenaar JW
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients.
    Zuur MA; Ghimire S; Bolhuis MS; Wessels AMA; van Altena R; de Lange WCM; Kosterink JGW; Touw DJ; van der Werf TS; Akkerman OW; Alffenaar JWC
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29439978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of Second-Line Antituberculosis Drugs in Children with Multidrug-Resistant Tuberculosis in India.
    Hemanth Kumar AK; Kumar A; Kannan T; Bhatia R; Agarwal D; Kumar S; Dayal R; Singh SP; Ramachandran G
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.